Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers.

The oncologist - 10 Mar 2025

Mahipal Amit, Bucheit Leslie, Zhang Nicole, Barnett Reagan M, Storandt Michael H, Chakrabarti Sakti

Abstract excerpt

BACKGROUND: Impact of BRAF V600E mutations (BRAFV600E), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumor-agnostic approvals for patients with BRAFV600E, understanding the frequency and impact of BRAF alterations across...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Gastrointestinal Neoplasms

Share to Liquid Biopsy

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 40163685
DOI: 10.1093/oncolo/oyaf044
PMCID: PMC11957259

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers.PMID 40163685Read ↗

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.Semantic proximity Read ↗

Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers.Semantic proximity Read ↗

Pan-Cancer Analyses Reveal Disparities in Tumor Genomic Profiles by Race/Ethnicity, Age, and SexSemantic proximity Read ↗

Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practiceSemantic proximity Read ↗

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAF Mutations: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

The clinical, genomic, and transcriptomic landscape of BRAF mutant cancersSemantic proximity Read ↗

The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.Semantic proximity Read ↗

Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.Semantic proximity Read ↗

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.Semantic proximity Read ↗

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesionsSemantic proximity Read ↗

Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.